Investigational drug · Phase 2
AZD2693
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Nonalcoholic Steatohepatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
5
Any phase or sponsor naming "AZD2693"
First trial start
2023
Mar 15, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD2693", any sponsor or status.
Conditions studied
As listed on its trial records.
- Nonalcoholic Steatohepatitis
Approved drugs for the same conditions: MASH (fatty liver disease) · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD2693" as an intervention, largest first.
- A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With FibrosisPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT05809934 · 220 participants · Start Mar 15, 2023 · Primary completion Jul 14, 2025
Drug: AZD2693 · For: Nonalcoholic Steatohepatitis
Sites: Chandler, Arizona; Peoria, Arizona; Surprise, Arizona · 163 sites in all
AstraZenecaAstraZeneca (AZN)
NCT04483947 · 74 participants · Start Nov 6, 2020 · Primary completion Dec 18, 2023
Drug: AZD2693 · For: Non-alcoholic Steatohepatitis (NASH)
Sites: Chula Vista, California; La Mesa, California; Montclair, California · 16 sites in all
AstraZenecaAstraZeneca (AZN)
NCT04142424 · 73 participants · Start Oct 28, 2019 · Primary completion Nov 12, 2021
Drug: AZD2693; Placebo · For: Metabolic Disorders; Non-alcoholic Steatohepatitis
Sites: Glendale, California
AstraZenecaAstraZeneca (AZN)
NCT05107336 · 44 participants · Start Nov 25, 2021 · Primary completion Mar 21, 2023
Drug: AZD2693; Placebo · For: Healthy Participants
Sites: Sumida-ku, Japan
AstraZenecaAstraZeneca (AZN)
NCT05919069 · 35 participants · Start Jun 16, 2023 · Primary completion Sep 16, 2024
Drug: AZD2693 · For: Hepatic Impairment
Sites: Rialto, California; Miami Lakes, Florida; Orlando, Florida
Newest research
PubMed records naming it or its code names, newest first.
- AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials.
Armisen J, Rauschecker M, Sarv J, et al. · J Hepatol 2025
Also in development for Nonalcoholic Steatohepatitis
- Saroglitazar MagnesiumPhase 35 trials
Zydus Therapeutics Inc. · Primary Biliary Cholangitis, Nonalcoholic Steatohepatitis, Fibrosis
- EfinopegdutideMK-6024, HM12525APhase 22 trials
Merck & Co. · Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
- HU6Phase 22 trials
Rivus Pharmaceuticals, Inc. · Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.